drugset / Trial / NCT00934479

Intestinal Microecology in Chronic Constipation

NCT00934479

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to determine whether the bacteria normally present in the bowels are different in people with constipation and to see what effect the treatment with the Food and Drug Administration (FDA) - approved drug, lubiprostone, has on these bacteria.

Timeline

Start
2010-04
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lubiprostone Small molecule 8 ug Oral
Subject Lubiprostone Small molecule 24 ug Oral